Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | PPIA | P62937 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572869 | 0.85 | LTA4H (0.58) | LTA4HMAPK14PPIAL3MBTL1LIPE | |
| SCHEMBL10460602 | 0.84 | LTA4H (0.54) | LTA4HMAPK14PPIAL3MBTL1LIPE | |
| SCHEMBL1932458 | 0.83 | LTA4H (0.65) | LTA4HMAPK14PPIAL3MBTL1LIPE | |
| SCHEMBL28312955 | 0.83 | LTA4H (0.60) | LTA4HMAPK14PPIAL3MBTL1LIPE | |
| SCHEMBL1573299 | 0.83 | LTA4H (0.60) | LTA4HMAPK14PPIAL3MBTL1LIPE | |
| SCHEMBL5740565 | 0.82 | LTA4H (0.55) | LTA4HMAPK14PPIASGMS2ALPG | |
| SCHEMBL6246736 | 0.82 | MRGPRX4 (0.43) | LTA4HMAPK14PPIAL3MBTL1MAPT | |
| SCHEMBL18836470 | 0.82 | LTA4H (0.51) | LTA4HMAPK14PPIASGMS2ALPG | |
| SCHEMBL3946071 | 0.81 | PPIA (0.52) | LTA4HMAPK14PPIASGMS2 | |
| SCHEMBL4898090 | 0.80 | LTA4H (0.45) | LTA4HMAPK14PPIAL3MBTL1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115010712-A | TDO2 inhibitors | 基因泰克公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017099237-A1 | AMINOAZOLE DERIVATIVE | 帝人ファーマ株式会社 | 2017-06-15 | — | — | WO | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| WO-2007080325-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
| US-7183278-B1 | Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1134214-A1 | PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| US-4478834-A | Dihydropyridines and their use in the treatment of asthma | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4409226-A | ANTIULCER AGENTS | SCHERING CORPORATION (US) | 1983-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | LTA4H 1784/4885MAPK14 4683/4885PPIA 343/4885 |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PTH1R, VDR, P2RY1 | LTA4H 1575/4885MAPK14 3362/4885PPIA 2730/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | LTA4H 1054/4885MAPK14 3174/4885PPIA 297/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | LTA4H 1436/4885MAPK14 3914/4885PPIA 341/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | LTA4H 1054/4885MAPK14 3174/4885PPIA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.